mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

mAbxience-HP-AI

More Like This

PR Newswire associated0

mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

Canada-UK Collaboration Developing AI-powered Bioreactors to Revolutionise Biopharmaceutical Manufacturing

PR Newswire associated0

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

PR Newswire associated0

mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease